TNX-1500
TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kd values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection[1][2].
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Species Reactivity
Human
IC50 & Target
[1]|
CD40L |
FcγRI 8.7 nM (Kd) |
FcγRIIaH 7100 nM (Kd) |
FcγRIIbF 4900 nM (Kd) |
FcγRIIIaF 8000 nM (Kd) |
FcγRIIIaV 6000 nM (Kd) |
In Vitro
TNX-1500 (500 nM) does not induce platelet activation in cynomolgus monkey or human whole blood when complexed with sCD154[1].
TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (KD values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Lassiter G, et al. TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival. Am J Transplant. 2023;23(8):1171-1181. [Content Brief]
[2]. Miura S, et al. TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival. Am J Transplant. 2023;23(8):1182-1193. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TNX-1500 Related Classifications
HY-P991921 Related Classifications
Powered by Bioz
Keywords
- TNX-1500
- TNX1500
- TNX 1500
- TNF Receptor
- Fc Receptor (FcR)
- FcγRIIIaF
- allograft rejection
- FcγRIIIaV
- cynomolgus monkey
- antidonor alloantibody elaboration
- nonhuman primates
- platelets
- TEFF/TREG ratio
- FcγRIIaH
- CD40
- cardiac allograft vasculopathy
- regulatory T cells
- sCD154
- kidney transplantation
- chronic rejection
- FcγRI
- CAV
- nonhuman primate heart allotransplant models
- human whole blood
- ABO blood type-compatible
- CD154
- FcγRIIbF
- effector T cells
- kidney allograft rejection
- T cell costimulation pathways
- MHC-mismatched
- Inhibitor
- inhibitor
- inhibit